NCT07524634 2026-04-13
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
Case Comprehensive Cancer Center
GlaxoSmithKline
Peking University People's Hospital
Nanjing IASO Biotechnology Co., Ltd.